Vision
Global Leading Company
BT/NT/IT
-
Self-developed convergence technology
-
Foundational technology applicable to various diagnostic services
Unrivalled production and research infrastructure
-
CAPA of over 100 million tests per year
-
Acquired GMP, ISO13485, and MDSAP certifications
Global sales network and licensing
-
Acquired licensing from 52 countries including the US Food and Drug Administration
-
World's first COVID-19-related antigen/antibody CE CoC
-
Korea's first smart female hormone product certification and approval
Differentiated product lineup
-
Possesses a diverse diagnostic product lineup including female hormones and allergies
(Surearly SMART, S-Blot 3 PLUS, INCLIX F-100)
Key Strengths
Fully automatic multiplexed immunoblot device
-
Developed in 2013
-
Used for the diagnosis of allergies at general hospitals and examination centers nationwide
Digital healthcare Surearly SMART
-
Diagnoses diseases in females by combining the urine concentration patterns of five female hormones
-
Manages the female life cycle through self-diagnosis
COVID-19 Diagnostic Kit
-
Exported to over 50 countries
-
First domestic company to acquire European conformity certification (CE CoC) for self-testing